Skip to main content
Year archive

Oncopeptides — 2020 filings

All 59 regulatory filings released by Oncopeptides (ONCO) in 2020, sourced directly from the official regulator.

59 Filings
2020 Period
2020 filings (59)
Filing Released Lang
Kommuniké från extra bolagstämma i Oncopeptides AB (publ)
AGM Information
2020-12-04 Swedish
Bulletin from the Extraordinary General Meeting in Oncopeptides AB (publ)
AGM Information
2020-12-04 English
Antal aktier och röster i Oncopeptides
Share Issue/Capital Change
2020-11-30 Swedish
Number of shares and votes in Oncopeptides
Declaration of Voting Results & Voting Rights Announcements
2020-11-30 English
Report Publication Announcement 2020
Report Publication Announcement
2020-11-19 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q3 2020
2020-11-19 English
Extra bolagsstämma i Oncopeptides AB (publ)
Proxy Solicitation & Information Statement
2020-11-03 Swedish
Extraordinary General Meeting in Oncopeptides AB (publ)
AGM Information
2020-11-03 English
Oncopeptides ingår låneavtal om 40 miljoner euro med EIB
Capital/Financing Update
2020-10-14 Swedish
Oncopeptides signs € 40 million loan agreement with the EIB
Capital/Financing Update
2020-10-14 English
FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma
Earnings Release FY 2021
2020-08-29 English
FDA beviljar en prioriterad granskning av melflufen för patienter med trippelklassrefraktärt multipelt myelom
Regulatory Filings
2020-08-29 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q2 2020
2020-08-26 Swedish
Investor Presentation 2020
Investor Presentation
2020-08-26 English
Oncopeptides starts the phase 2 PORT study comparing peripheral versus central administration of melflufen and dexamethasone in multiple myeloma
Regulatory Filings
2020-08-04 English
Oncopeptides startar fas 2-studien PORT som jämför perifer administrering med central administrering av melflufen och dexametason vid multipelt myelom
Regulatory Filings
2020-08-04 Swedish
Major Shareholding Notification 2020
Major Shareholding Notification
2020-08-03 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-08-03 Swedish
Number of shares and votes in Oncopeptides
Declaration of Voting Results & Voting Rights Announcements
2020-07-31 English
Antal aktier och röster i Oncopeptides
Share Issue/Capital Change
2020-07-31 Swedish
Major Shareholding Notification 2020
Major Shareholding Notification
2020-07-13 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-07-10 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-07-01 English
Uppdaterad version. Oncopeptides offentliggör ledarförändringar: Jakob Lindberg tar över rollen som forskningschef och Marty J Duvall utses till vd
Board/Management Information
2020-06-30 Swedish
Oncopeptides offentliggör ledarförändringar: Jakob Lindberg tar över rollen som forskningschef och Marty J Duvall utses till vd
Board/Management Information
2020-06-30 Swedish
Oncopeptides announces leadership changes: Jakob Lindberg assumes a new role as CSO, and Marty J Duvall is appointed CEO
Board/Management Information
2020-06-30 English
Number of shares and votes in Oncopeptides
Share Issue/Capital Change
2020-06-30 English
Antal aktier och röster i Oncopeptides
Share Issue/Capital Change
2020-06-30 Swedish
Oncopeptides lämnar in en ansökan om villkorat marknadsgodkännande till FDA för patienter med trippelklassrefraktärt multipelt myelom
Regulatory Filings
2020-06-30 Swedish
Oncopeptides submits a New Drug Application to the FDA for accelerated approval of melflufen in triple-class refractory multiple myeloma patients
Regulatory Filings
2020-06-30 English
Ny analys bekräftar att patienter med multipelt myelom i OCEAN-studien står kvar på behandling längre än väntat - resultat förväntas H1-2021
Regulatory Filings
2020-06-01 Swedish
New analysis confirms that multiple myeloma patients in the OCEAN study stay on treatment longer than previously estimated - results expected H1-2021
Legal Proceedings Report
2020-06-01 English
Number of shares and votes in Oncopeptides
Declaration of Voting Results & Voting Rights Announcements
2020-05-29 English
Antal aktier och röster i Oncopeptides
Declaration of Voting Results & Voting Rights Announcements
2020-05-29 Swedish
Oncopeptides reinitiates patient enrollment to the melflufen clinical program following a temporary pause due to the COVID-19 pandemic
Regulatory Filings
2020-05-28 English
Oncopeptides återupptar patientrekryteringen till kliniska utvecklingsprogrammet för melflufen efter att den tillfälligt pausats på grund av COVID-19-pandemin
Regulatory Filings
2020-05-28 Swedish
Kommuniké från årsstämma i Oncopeptides AB (publ)
AGM Information
2020-05-26 Swedish
Bulletin from the Annual General Meeting in Oncopeptides AB (publ)
AGM Information
2020-05-26 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Q1 2020
2020-05-26 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q1 2020
2020-05-26 English
Oncopeptides slutför rekryteringen till den pivotala fas 3-studien OCEAN i relapserande refraktärt multipelt myelom – 450 patienter har inkluderats
Regulatory Filings
2020-05-22 Swedish
Oncopeptides completes enrollment to the pivotal phase 3 study OCEAN for relapsed refractory multiple myeloma - 450 patients included
Regulatory Filings
2020-05-22 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-05-11 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-05-08 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-05-07 English
Oncopeptides har genomfört en riktad nyemission om cirka 1 414 miljoner kronor (144 MUSD)
Capital/Financing Update
2020-05-06 Swedish
Oncopeptides has completed a directed share issue raising approximately SEK 1,414 million (USD 144 M)
Capital/Financing Update
2020-05-06 English
Oncopeptides avser att genomföra en riktad nyemission
Share Issue/Capital Change
2020-05-05 Swedish
Oncopeptides intends to carry out a directed share issue
Capital/Financing Update
2020-05-05 English
Annual Report 2019
Annual Report FY 2019
2020-04-28 Swedish
Annual Report 2019
Annual Report FY 2019
2020-04-28 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-04-14 English
Oncopeptides tillkännager att den finala tumörsvarsfrekvensen i den pivotala melflufenstudien HORIZON var 26% för trippelklassrefraktära RRMM- patienter
Earnings Release Q2 2020
2020-03-26 Swedish
Oncopeptides announces 26% Overall Response Rate of melflufen in triple-class refractory multiple myeloma patients from the pivotal HORIZON study
Earnings Release Q2 2020
2020-03-26 English
Oncopeptides informerar om hur COVID-19 påverkar det kliniska utvecklingsprogrammet för melflufen
Regulatory Filings
2020-03-20 Swedish
Oncopeptides provides update regarding COVID-19 impact on the melflufen clinical program
Regulatory Filings
2020-03-20 English
Declaration of Voting Results & Voting Rights Announcements 2020
Declaration of Voting Results & Voting Rights Announcements
2020-03-17 English
Earnings Release 2019
Earnings Release FY 2019
2020-02-20 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report FY 2019
2020-02-20 English